Tyra Biosciences TYRA Income Statement (2020-2026)

NASDAQ TYRA
$28.17 +3.31 (+13.31%)
As of: Sep 4, 2026 · 12:50 PM EDT
Reported Financials

Tyra Biosciences Quarterly Income Statement

Periods 24 quarters
Latest Jun 2026

Tyra Biosciences reported net income of -$46.24M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
9.16M13.78M41.70M41.90M42.14M42.35M42.54M42.82M42.93M43.02M52.47M52.74M52.87M50.75M53.09M53.23M53.32M53.71M59.47M59.66M
Operating items
Research & DevelopmentR&D
5.48M7.25M9.64M12.05M10.91M10.40M10.41M12.16M19.27M20.68M17.20M18.00M22.70M22.18M24.96M24.31M25.47M28.19M33.47M39.20M
Selling, General & AdministrativeSG&A
1.15M2.68M5.19M3.38M2.73M4.62M3.93M3.85M4.69M4.96M5.12M5.54M5.91M7.56M6.89M7.14M7.47M8.33M8.53M9.81M
Operating ExpensesOpex
6.64M9.93M14.83M15.43M13.64M15.02M14.33M16.01M23.96M25.63M22.32M23.53M28.60M29.74M31.85M31.45M32.94M36.52M42.00M49.00M
Operating IncomeOp. Inc
-6.64M-9.93M-14.83M-15.43M-13.64M-15.02M-14.33M-16.01M-23.96M-25.63M-22.32M-23.53M-28.60M-29.74M-31.85M-31.45M-32.94M-36.52M-42.00M-49.00M
EBIT
-6.64M-9.93M-14.83M-15.43M-13.64M-15.02M-14.33M-16.01M-23.96M-25.63M-22.32M-23.53M-28.60M-29.74M-31.85M-31.45M-32.94M-36.52M-42.00M-49.00M
Non-operating items
Non Operating Interest Expenses
0.01M0.00M0.01M0.01M0.01M0.03M0.00M0.02M
Interest & Investment IncomeInt & Inv Inc
0.00M0.01M0.02M0.35M1.13M2.16M2.45M2.74M2.81M2.80M4.13M4.83M4.59M4.17M3.70M3.35M3.08M2.68M2.69M3.44M
Other Non Operating IncomeOther Non Op Inc.
0.01M-0.01M
Non Operating IncomeNon Op. Inc.
-0.01M0.00M0.01M0.33M1.14M2.12M2.45M2.74M2.81M2.80M4.13M4.83M4.59M4.17M3.70M3.35M3.08M2.68M2.69M3.44M
Net income details
EBT
-6.64M-9.93M-14.83M-15.10M-12.52M-12.89M-11.88M-13.29M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.10M-29.87M-33.83M-39.30M-45.56M
Profit After TaxPAT
-6.64M-9.93M-14.83M-15.10M-12.51M-12.89M-11.88M-13.27M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.35M-29.87M-33.88M-39.30M-46.24M
Income from Continuing OperationsIncome (Continuing)
-6.64M-9.93M-14.83M-15.10M-12.52M-12.89M-11.88M-13.29M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.10M-29.87M-33.83M-39.30M-45.56M
Consolidated Net IncomeConsol Net Inc.
-6.64M-9.93M-14.83M-15.10M-12.52M-12.89M-11.88M-13.29M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.10M-29.87M-33.83M-39.30M-45.56M
Income towards Parent CompanyParent Net Inc
-6.64M-9.93M-14.83M-15.10M-12.52M-12.89M-11.88M-13.29M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.10M-29.87M-33.83M-39.30M-45.56M
Net Income towards Common StockholdersNet Income
-6.64M-9.93M-14.83M-15.10M-12.52M-12.89M-11.88M-13.29M-21.15M-22.83M-18.19M-18.70M-24.02M-25.57M-28.15M-28.10M-29.87M-33.83M-39.30M-45.56M
Additional items
EPS (Basic)
-0.72-0.72-0.36-0.36-0.30-0.31-0.28-0.31-0.49-0.53-0.35-0.32-0.41-0.45-0.47-0.47-0.50-0.57-0.64-0.69
EPS (Diluted)
-0.72-0.72-0.36-0.36-0.30-0.31-0.28-0.31-0.49-0.53-0.35-0.32-0.41-0.45-0.47-0.47-0.50-0.57-0.64-0.69
Shares Outstanding
9.16M13.78M41.55M41.78M42.00M41.88M42.39M42.59M42.87M42.70M52.23M58.67M58.87M57.22M59.34M59.55M59.67M59.60M61.75M65.99M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
9.16M13.78M41.55M41.78M42.00M41.88M42.39M42.59M42.87M42.70M52.23M58.67M58.87M57.22M59.34M59.55M59.67M59.60M61.75M65.99M
EBITDA
-6.64M-9.93M-14.83M-15.43M-13.64M-15.02M-14.33M-16.01M-23.96M-25.63M-22.32M-23.53M-28.60M-29.74M-31.85M-31.45M-32.94M-36.52M-42.00M-49.00M
Interest ExpensesInt Expense
0.01M0.00M0.01M0.01M0.01M0.03M0.00M0.02M